AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15926966 — intervention group
Group type: COMPARATOR
Intervention: CRNs and ward-based nurses
Number of subjects: 378
Study 11209104 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven week pulmonary rehabilitation programme
Number of subjects: 44
Study 11209104 — intervention group
Group type: COMPARATOR
Intervention: Four week pulmonary rehabilitation programme
Number of subjects: 44
Study 9644112 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion (30 micrograms/h for 2-6 h)
Number of subjects: 24
Study 9644112 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 24
Study 7840523 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (loading dose of 160 mg on the first day)
Number of subjects: 473
Study 7840523 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant tamoxifen
Number of subjects: 473
Study 3398697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP, 30 micrograms/kg/h)
Number of subjects: 19
Study 3398697 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 19
Study 31920008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib in EGFR-positive tumors
Number of subjects: 0
Study 31920008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in EGFR-positive tumors
Number of subjects: 0
Study 31920008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in EGFR-negative tumors
Number of subjects: 0
Study 31920008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib in EGFR-negative tumors
Number of subjects: 0
Study 31920008 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-negative tumors
Number of subjects: 0
Study 31920008 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-positive tumors
Number of subjects: 0
Study 29915988 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate beverage (400 mL evening before and 400 mL morning before surgery)
Number of subjects: 153
Study 29915988 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored water, same quantity as carbohydrate beverage)
Number of subjects: 153
Study 29915988 — intervention group
Group type: COMPARATOR
Intervention: Fasting from midnight until surgery (Group MN-NPO)
Number of subjects: 153
Study 27070228 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveLight Allegretto Wave Eye‐Q 400‐Hz excimer laser
Number of subjects: 50
Study 27070228 — intervention group
Group type: COMPARATOR
Intervention: VISX Star S4 IR CustomVue excimer laser
Number of subjects: 50
Study 24797760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDD-R)
Number of subjects: 2010
Study 24797760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing (VVI-R)
Number of subjects: 2010
Study 24797760 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree AV-block
Number of subjects: 2010
Study 24797760 — intervention group
Group type: COMPARATOR
Intervention: Normal PR interval
Number of subjects: 2010
Study 22375604 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation
Number of subjects: 12
Study 22375604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA supplementation)
Number of subjects: 12
Study 20051525 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting the Strong-Willed Child (PSWC) book
Number of subjects: 52
Study 20051525 — intervention group
Group type: COMPARATOR
Intervention: Touchpoints: Three to Six (comparison book)
Number of subjects: 52
Study 17698986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala/Ala(94) mutation
Number of subjects: 1453
Study 17698986 — intervention group
Group type: COMPARATOR
Intervention: Wild-type (Thr/Thr(94))
Number of subjects: 1453
Study 17698986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid/heparin-somatostatin-insulin-glucagon clamps
Number of subjects: 1453
Study 17698986 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic-hyperinsulinemic clamps
Number of subjects: 1453
Study 16222155 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day
Number of subjects: 38
Study 16222155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12002967 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-synthesized speech by a disabled speaker
Number of subjects: 0
Study 12002967 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-synthesized speech by a nondisabled speaker
Number of subjects: 0
Study 12002967 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural speech by a disabled speaker
Number of subjects: 0
Study 12002967 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural speech by a nondisabled speaker
Number of subjects: 0
Study 10682463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine 100 mg in 5% glucose 500 ml intravenous, adjusted drip speed starting at 8 drips per minute, oral ritodrine after 12 hours if no contractions or bleeding.
Number of subjects: 50
Study 10682463 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 50
Study 7699441 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl reinjection immediately after stress‐redistribution planar imaging (Group A)
Number of subjects: 402
Study 7699441 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl reinjection on a separate day followed by rest‐redistribution imaging (Group B)
Number of subjects: 402
Study 7699441 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 402
Study 7699441 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 402
Study 2665305 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoseryl and film-forming glue 'Statizol'
Number of subjects: 300
Study 2665305 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of ulcers
Number of subjects: 300
Study 989965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight sodium heparin (mean m.w. 9,000)
Number of subjects: 6
Study 989965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium heparin (m.w. 15,000)
Number of subjects: 6
Study 989965 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin
Number of subjects: 6
Study 989965 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight sodium heparin (mean m.w. 22,000)
Number of subjects: 6
Study 29334290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 144
Study 29334290 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 144
Study 29976305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) management strategy
Number of subjects: 200
Study 29976305 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography management strategy
Number of subjects: 200
Study 27373720 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 104
Study 27373720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid procedure
Number of subjects: 104
Study 27373720 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally minimally invasive surgery
Number of subjects: 104
Study 27373720 — intervention group
Group type: COMPARATOR
Intervention: Recruitment rate
Number of subjects: 104
Study 27373720 — intervention group
Group type: COMPARATOR
Intervention: Pain assessment
Number of subjects: 104
Study 27373720 — intervention group
Group type: COMPARATOR
Intervention: Patient-reported outcomes
Number of subjects: 104
Study 27373720 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 104
Study 27373720 — intervention group
Group type: COMPARATOR
Intervention: Length of stay
Number of subjects: 104
Study 24192751 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg telaprevir (TVR) at 8 h intervals
Number of subjects: 52
Study 24192751 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg telaprevir (TVR) at 12 h intervals
Number of subjects: 52
Study 22251974 — intervention group
Group type: COMPARATOR
Intervention: Cervical Laminectomy and Fusion (CLF)
Number of subjects: 16
Study 22251974 — intervention group
Group type: EXPERIMENTAL
Intervention: Expansile Cervical Laminoplasty (ECL)
Number of subjects: 16
Study 19081706 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (0.1 mg . kg(‐1) . d(‐1))
Number of subjects: 21
Study 19081706 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous placebo
Number of subjects: 21
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy by therapists
Number of subjects: 58
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily therapy by more than one therapist
Number of subjects: 58
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 58
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 58
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech pathology
Number of subjects: 58
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb therapy
Number of subjects: 58
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of family members during therapy
Number of subjects: 58
Study 17225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle weakness and left hemiparesis
Number of subjects: 58
Study 16360523 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional surgical technique (submucosal resection)
Number of subjects: 225
Study 16360523 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric tissue reduction (RFVTR)
Number of subjects: 225
Study 16360523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 225
Study 12482192 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 doses of the HiB vaccine (PPR‐D, Connaught) starting at 3 months of life
Number of subjects: 116000
Study 12482192 — intervention group
Group type: COMPARATOR
Intervention: 0 doses of the HiB vaccine (control group)
Number of subjects: 116000
Study 9935122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 9 mg daily for 15 days, followed by a stepwise decrease in dosage, plus 300 IU of hMG daily for 10 days
Number of subjects: 36
Study 9935122 — intervention group
Group type: COMPARATOR
Intervention: Placebo, plus 300 IU of hMG daily for 10 days
Number of subjects: 36
Study 7769049 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182780, 12 mg/day i.m. for 7 days (n = 19)
Number of subjects: 30
Study 7769049 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n = 11)
Number of subjects: 30
Study 7769049 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182780
Number of subjects: 30
Study 2180233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B live attenuated intranasal vaccine (maximum potency, 1:2 dilution, titre of 10(7.0) EID50)
Number of subjects: 0
Study 2180233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2180233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B live attenuated intranasal vaccine
Number of subjects: 0
Study 476709 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl-CCNU and beta-2'-deoxythioguanosine
Number of subjects: 108
Study 476709 — intervention group
Group type: EXPERIMENTAL
Intervention: DGA
Number of subjects: 108
Study 476709 — intervention group
Group type: COMPARATOR
Intervention: VP-16-213
Number of subjects: 108
Study 476709 — intervention group
Group type: COMPARATOR
Intervention: Previous chemotherapy with nitrosourea
Number of subjects: 108
Study 31757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine users
Number of subjects: 88
Study 31757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine users with negative drug screen
Number of subjects: 88
Study 30583957 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support providing patient-level clinically important traumatic brain injury risk estimates and management recommendations
Number of subjects: 3859
Study 30583957 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Number of subjects: 3859
Study 30583957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clinical decision support)
Number of subjects: 3859
Study 29228934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application simulator (MAS)
Number of subjects: 27
Study 29228934 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional revision resources
Number of subjects: 27
Study 29228934 — intervention group
Group type: EXPERIMENTAL
Intervention: No formal revision resources
Number of subjects: 27
Study 26528654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reactivity measured by the Leiden Index of Depression Sensitivity (LEIDS)
Number of subjects: 116
Study 26528654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination (a component of cognitive reactivity)
Number of subjects: 116
Study 26528654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional cognitions measured by the Dysfunctional Attitudes Scale
Number of subjects: 116
Study 23403877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (non-core foods)
Number of subjects: 231
Study 23403877 — intervention group
Group type: COMPARATOR
Intervention: Cluster 1 (dietary guidelines)
Number of subjects: 231
Study 21500104 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0
Study 21500104 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 0
Study 19285833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamboo shoot diet (360 g)
Number of subjects: 8
Study 19285833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 25 g of cellulose
Number of subjects: 8
Study 19285833 — intervention group
Group type: COMPARATOR
Intervention: Dietary fiber-free diet (control)
Number of subjects: 8
Study 17530960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Group (SG)
Number of subjects: 93
Study 17530960 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Group (PG)
Number of subjects: 93
Study 17530960 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 93
Study 15068645 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 36
Study 11463772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg) alone
Number of subjects: 10
Study 11463772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine after domperidone (20 mg) pretreatment
Number of subjects: 10
Study 11463772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 10
Study 9879155 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrodin intramuscularly
Number of subjects: 20
Study 9879155 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrodin HP subcutaneously
Number of subjects: 20
Study 1431192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowatinex
Number of subjects: 87
Study 1431192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 3893509 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms daily
Number of subjects: 26
Study 3893509 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 400 micrograms daily
Number of subjects: 26
Study 3893509 — intervention group
Group type: COMPARATOR
Intervention: Control group (prednisolone)
Number of subjects: 26
Study 31028038 — intervention group
Group type: EXPERIMENTAL
Intervention: MH-COPD intervention group (n=50 patients)
Number of subjects: 100
Study 31028038 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (UC-COPD) (n=50 patients)
Number of subjects: 100
Study 29150482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening (invited group)
Number of subjects: 77080
Study 29150482 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 77080
Study 26442791 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers + icon arrays
Number of subjects: 276
Study 26442791 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers + experienced format
Number of subjects: 276
Study 26442791 — intervention group
Group type: COMPARATOR
Intervention: Numbers + icon array format
Number of subjects: 276
Study 25099689 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA handset exposure at 6 W/kg
Number of subjects: 15
Study 25099689 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA handset exposure at 1.5 W/kg
Number of subjects: 15
Study 25099689 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 15
Study 22232018 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P (group-based universal parent training program)
Number of subjects: 1675
Study 22232018 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 1675
Study 19387822 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level participatory intervention to increase influenza vaccination
Number of subjects: 0
Study 19387822 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level participatory intervention
Number of subjects: 0
Study 19387822 — intervention group
Group type: COMPARATOR
Intervention: Control building (no specific intervention mentioned)
Number of subjects: 0
Study 18247252 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear exercise testing protocol
Number of subjects: 28
Study 18247252 — intervention group
Group type: COMPARATOR
Intervention: Stepwise exercise testing protocol
Number of subjects: 28
Study 15072254 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) in volume ratios of 2:1 (Group II)
Number of subjects: 50
Study 15072254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) in volume ratios of 1:2 (Group IV)
Number of subjects: 50
Study 15072254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) in volume ratios of 0:1 (Group V)
Number of subjects: 50
Study 15072254 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) in volume ratios of 1:0 (Group I)
Number of subjects: 50
Study 12002198 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin
Number of subjects: 0
Study 12002198 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 0
Study 9825502 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to bacterial antigens (Reglicolipid, Streptococcus agalactiae polysaccharide, Staphylococcus aureus teichoic acid)
Number of subjects: 2
Study 7797824 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole (40 mg once daily)
Number of subjects: 249
Study 7797824 — intervention group
Group type: COMPARATOR
Intervention: ranitidine (150 mg b.i.d.)
Number of subjects: 249
Study 7797824 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole
Number of subjects: 249
Study 7797824 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 249
Study 2121268 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g alcohol in concentrations of 75, 180 and 300 ml/l water; RMR measured for 60 min; thermic effect measured for 90 min.
Number of subjects: 22
Study 2121268 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g alcohol in a 180 ml/l solution plus a meal of food (2 MJ); DIT measured for 240 min.
Number of subjects: 22
Study 2121268 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic meal of food alone (2.55 MJ) plus a placebo aperitif containing no alcohol; DIT measured for 240 min.
Number of subjects: 22
Study 385764 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4025 live recombinant strain (10(7.2) EID 50/dose, one or two doses at 2 weeks' interval)
Number of subjects: 253
Study 385764 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine (360 i.u. A/Port Chalmers/1/73 (H3N2), 300 i.u. A/Scotland/840/74 (H3N2), 300 i.u. B/Hong Kong/8/73, 300 i.u./dose, one injection)
Number of subjects: 253
Study 385764 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 253
Study 30561704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1 g every eight hours, three doses)
Number of subjects: 141
Study 30561704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (1 g every eight hours, three doses)
Number of subjects: 141
Study 30561704 — intervention group
Group type: COMPARATOR
Intervention: No acetaminophen
Number of subjects: 141
Study 30561704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 141
Study 28509573 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 128
Study 28509573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 28509573 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine + Parent Training (PT)
Number of subjects: 128
Study 28509573 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Parent Training (PT)
Number of subjects: 128
Study 26066761 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma extract with visible light phototherapy (VLRT)
Number of subjects: 21
Study 26066761 — intervention group
Group type: COMPARATOR
Intervention: Simulated visible light phototherapy (VLST)
Number of subjects: 21
Study 23901394 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen neck wrap targeting the carotid arteries at the neck
Number of subjects: 55
Study 23901394 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 55
Study 21606394 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 2502
Study 21606394 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 2502
Study 21606394 — intervention group
Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 2502
Study 21606394 — intervention group
Group type: EXPERIMENTAL
Intervention: biomarker+ only
Number of subjects: 2502
Study 20139856 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX/AZA (Azathioprine 2-2.5 mg/kg/day)
Number of subjects: 46
Study 20139856 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX/HC (Hydrocortisone 250 mg intravenously)
Number of subjects: 46
Study 16914835 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS‐Cog
Number of subjects: 15
Study 16914835 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE
Number of subjects: 15